Back to results
US 2021/0061830 A1Published application
Mito-lonidamine, compositions and methods of use
AssigneesThe Medical College of Wisconsin, Inc., Aix-Marseille Universite
InventorsBalaraman KALYANARAMAN, Micael J. HARDY, Olivier OUARI
Life of this patent
Estimating the term…
Abstract
The present invention relates to mito-lonidamine compounds, compositions and methods of use in the treatment of cancer.
Claims18
A mito-lonidamine compound of formula I:
- wherein L is a linker selected from an C2-C20 alkyl, an amino acid, benzyl, ramificiation of the alkyl side chain, a C2-C20 alkene or PEG,
- n is a positive integer selected from 2-20,
- and X is any halogen, 2,2,2-trifluoroacetic acid (TFA) or acetic acid.
A method of treating cancer in a subject in need thereof, the method comprising administering an effective amount of a mito-lonidamine compound of formula I:
- wherein L is a linker selected from an C2-C20 alkyl, an amino acid, benzyl, ramificiation of the alkyl side chain, a C2-C20 alkene or PEG,
- n is a positive integer selected from 2-20,
- and X is any halogen, 2,2,2-trifluoroacetic acid (TFA) or acetic acid.
A method of reducing cancer cell growth in a subject, the method comprising administering an effective amount of a mito-lonidamine compound of formula I:
- wherein L is a linker selected from an C2-C20 alkyl, an amino acid, benzyl, ramificiation of the alkyl side chain, a C2-C20 alkene or PEG,
- n is a positive integer selected from 2-20,
- and X is any halogen, 2,2,2-trifluoroacetic acid (TFA) or acetic acid.
Dependencies are inferred from the claim text.